CD4 augments the response of a T cell to agonist but not to antagonist ligands.
about
Cloning of ACP33 as a novel intracellular ligand of CD4Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virusInterplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagementMHC multimerization, antigen expression and the induction of APC amnesia in the developing immune response.Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune diseaseEngagement of T cell receptor triggers its recruitment to low-density detergent-insoluble membrane domains.How the immune system talks to itself: the varied role of synapsesTranscriptional and post-transcriptional mechanisms of glucocorticoid antiproliferative effects.Opposite effects of endogenous peptide-MHC class I on T cell activity in the presence and absence of CD8.Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor.The coreceptor CD4 is expressed in distinct nanoclusters and does not colocalize with T-cell receptor and active protein tyrosine kinase p56lckMolecular requirements for T cell recognition by a major histocompatibility complex class II-restricted T cell receptor: the involvement of the fourth hypervariable loop of the Valpha domain.The stimulation of low-affinity, nontolerized clones by heteroclitic antigen analogues causes the breaking of tolerance established to an immunodominant T cell epitope.Critical role for CD8 in T cell receptor binding and activation by peptide/major histocompatibility complex multimersDissociation of intracellular signaling pathways in response to partial agonist ligands of the T cell receptor.An antagonist peptide mediates positive selection and CD4 lineage commitment of MHC class II-restricted T cells in the absence of CD4T cell receptor (TCR)-mediated repertoire selection and loss of TCR vbeta diversity during the initiation of a CD4(+) T cell response in vivo.Inhibition of intrathymic T cell development by expression of a transgenic antagonist peptide.Therapeutic cancer vaccines in prostate cancer: the quest for intermediate markers of response.Suboptimal engagement of the T-cell receptor by a variety of peptide-MHC ligands triggers T-cell anergy.The molecular determinants of CD8 co-receptor function.Taming the TCR: antigen-specific immunotherapeutic agents for autoimmune diseases.Differential T-cell antigen receptor signaling mediated by the Src family kinases Lck and Fyn.Activated monocytes prime naïve T cells against autologous cancer: vigorous cancer destruction in vitro and in vivo.Efficient CD4 binding and immunosuppressive properties of the 13B8.2 monoclonal antibody are displayed by its CDR-H1-derived peptide CB1.The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain.CD4-independent T cells impair TCR triggering of CD4-dependent T cells: a putative mechanism for T cell affinity maturation.Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant regionSoluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research.Nonself-antigens are the cognate specificities of Foxp3+ regulatory T cells.T Cell Receptor Binding to a pMHCII Ligand Is Kinetically Distinct from and Independent of CD4.Fasciola hepatica cathepsin L suppresses sheep lymphocyte proliferation in vitro and modulates surface CD4 expression on human and ovine T cells.N-glycosylation bidirectionally extends the boundaries of thymocyte positive selection by decoupling Lck from Ca²⁺ signaling.Toward a predictive understanding of molecular recognition.Antagonism of cytotoxic T-lymphocyte activation by soluble CD8.Altered superantigenic ligands demonstrate the quantitative nature of T-cell activation.
P2860
Q24290610-7D70511B-4E3D-4428-B39D-13559A818300Q24645078-C0681644-251C-42B9-9B52-3D3567DA13AEQ28512242-BAFBD152-8A0C-41EF-B551-C74A156D86CFQ33547800-B18054C1-09BE-490C-BE91-39C3C74E526CQ33606814-28C9BDD6-2D10-4F85-AD9E-B37454808A21Q33889480-BA02F771-B7A1-446F-B09D-61E2EDC93259Q34320311-C0BAC79C-DE52-4DDE-8480-163F39330C4BQ34580606-3C2E0443-981B-42F1-ABF3-F799123AA1ADQ34983206-27D3EFB5-2930-4137-9DE7-AAE4D25100B9Q35111360-4691D458-32C4-43D6-BD8F-B1A7C183E534Q35280445-1AEAB0EB-0D33-4B82-B135-D8288B5A627BQ36367729-6C8DEE41-2DD6-4591-94CE-9AB963353F7EQ36375353-CFE7B918-A933-4F53-BD33-BAB5F581EDDBQ36375751-755D7C7E-CB0B-4959-832B-D145021475A6Q36400810-6C3D7A67-C445-4F03-9582-0BDFA6F37E95Q36402496-FB9FB05C-4BBE-4378-834A-F864F35A9807Q36404561-5AB32F00-F653-4BC6-858E-7BBCF4B276C8Q36734207-6636AB8D-5638-49A3-BB08-8313E24764C1Q37017101-079B6ABC-F3DA-4735-AFDE-0C4DC93B4400Q37651126-E0A27376-E099-4916-81E6-BDE071BB77E4Q38026943-429C4022-5034-4FDA-BC71-6E4C5674D209Q38477340-DB428212-4A68-480A-A952-BE143846843EQ39451191-A048E80E-0D99-4E34-BFFF-7D0FF0C7E244Q39458843-D836EC5A-FEF4-4E68-83D0-24A3AA547C01Q40768927-306DA8E6-A353-48DC-9C6E-DFDF28163080Q40794740-F552124B-2E24-4823-AE6B-9146554B09F9Q40827284-0F79EBA9-A941-462D-91C4-07FCB0E841A9Q41306886-5A6BF10B-C1D0-4387-B735-1808C5D5DAA2Q42017582-0A0F0C5E-0D0B-4157-9E11-A8F9BB34F430Q42114183-AC58FFA3-7F56-4549-8CE8-1DC9BE40710CQ43511256-B12C3A73-95C7-4FC3-8F4C-E2A2720DD392Q43902970-6B8EB61C-F1BC-4843-B817-EEB5632601F7Q46749545-1E813FD1-6886-4685-966E-4C90CD68F637Q47699978-0CD9B0EA-783A-4BBF-B6DF-C1034ED1E96EQ52534683-0A32283A-572C-4305-9849-16C9B18D8DC3Q53805171-F4401C52-9CB3-4BFF-829D-A9A891539C6F
P2860
CD4 augments the response of a T cell to agonist but not to antagonist ligands.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
CD4 augments the response of a T cell to agonist but not to antagonist ligands.
@en
CD4 augments the response of a T cell to agonist but not to antagonist ligands.
@nl
type
label
CD4 augments the response of a T cell to agonist but not to antagonist ligands.
@en
CD4 augments the response of a T cell to agonist but not to antagonist ligands.
@nl
prefLabel
CD4 augments the response of a T cell to agonist but not to antagonist ligands.
@en
CD4 augments the response of a T cell to agonist but not to antagonist ligands.
@nl
P2093
P1433
P1476
CD4 augments the response of a T cell to agonist but not to antagonist ligands.
@en
P2093
P304
P356
10.1016/S1074-7613(00)80359-3
P407
P577
1997-09-01T00:00:00Z